Ignite Creation Date:
2025-12-24 @ 8:00 PM
Ignite Modification Date:
2026-03-03 @ 2:23 AM
Study NCT ID:
NCT01941004
Status:
WITHDRAWN
Last Update Posted:
2017-04-21
First Post:
2013-09-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of Fingolimod in MS Patients in China
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Overview
Official Title:
A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis
Status:
WITHDRAWN
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: